端粒酶反转录酶启动子突变在甲状腺癌中的研究进展  

Progress of telomerase reverse transcriptase promoter mutations in thyroid cancer

作　　者：王鑫宇 宋文晓 周旭阳 史亚飞[2] Wang Xinyu;Song Wenxiao;Zhou Xuyang;Shi Yafei(Clinical Medical College,Jining Medical University,Jining 272002,China;Department of Thyroid Surgery,Affiliated Hospital of Jining Medical College,Jining 272000,China)

机构地区：[1]济宁医学院临床医学院,济宁272002 [2]济宁医学院附属医院甲状腺外科,济宁272000

出　　处：《肿瘤研究与临床》2024年第4期307-309,共3页Cancer Research and Clinic

摘　　要：端粒酶反转录酶(TERT)启动子突变在甲状腺癌中首次发现后,甲状腺癌的术前诊断及预后的分子标志物研究进入了新的阶段。虽然TERT启动子突变在甲状腺良性肿瘤中未发现,且在甲状腺乳头状微小癌中占比较低,但在甲状腺低分化癌和甲状腺间变性癌中的发病率较高。特别是当BRAF V600E与TERT启动子双突变共存时与疾病的特异性死亡率增加显著相关。TERT启动子突变作为甲状腺癌中的一个新癌基因,显现出极大的研究价值,文章就TERT启动子突变在甲状腺癌中的研究及临床意义进行综述。After the initial discovery of telomerase reverse transcriptase(TERT)promoter mutations in thyroid cancer,the investigation of preoperative diagnosis and prognostic indicators for thyroid cancer enters a new phase.Although TERT promoter mutations are not found in benign thyroid tumors and only account for a small portion of papillary thyroid microcarcinomas,they have a high incidence in poorly differentiated thyroid carcinomas and interstitial thyroid carcinomas.An increase of disease-specific mortality is associated with the coexistence of the BRAF V600E and TERT promoter double mutations.TERT promoter mutation is a novel oncogene in thyroid cancer and exhibits a considerable research value.This article reviews the research and clinical significance of TERT promoter mutations in thyroid cancer.

关 键 词：端粒酶反转录酶 甲状腺肿瘤 端粒酶反转录酶启动子突变 诊断 预后 

分 类 号：R736.1[医药卫生—肿瘤]